Will The Pace of M&A Pick Up Following The Biotech Sector’s Pounding?
With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
Clovis Oncology
CLVS
CLVS
$3.28
$0.10
3.3%
BATS BZX Real Time Price as of October 11, 2019, 4:00 p.m. EDT
View Interactive CLVS Charts
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring developing and commercializing innovative anti-cancer agents in the United States Europe and additional international markets.
News & Analysis: Clovis Oncology
The Fool has written over 100 articles on Clovis Oncology.
3 Cancer Treatment Stocks to Buy Right Now
These three beaten-down cancer stocks could prove to be amazing value plays.
Here's Why Clovis Oncology Fell as Much as 13.5% Today
Wall Street is questioning the value and purpose of a recent deal.
Near an All-Time Low, Is Clovis Oncology a Buy?
Investors need ongoing clinical trials to deliver -- and for the business to rein in expenses.
3 Stocks That Are Absurdly Cheap Right Now
If you are looking for stocks that offer investors value in an overpriced market, take a gander at this diverse trio.
Clovis Oncology (CLVS) Q2 2019 Earnings Call Transcript
CLVS earnings call for the period ending June 30, 2019.
Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today
The company reported a net loss of $120 million for the second quarter, which was much worse than analysts expected.
Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript
CLVS earnings call for the period ending March 31, 2019.
Here's Why Clovis Oncology Stock Dropped as Much as 13% Today
The company decided to discontinue an important clinical trial.
Here's Why Clovis Oncology Stock Jumped on Wednesday
Better-than-expected Rubraca sales were just what investors wanted to see.
